Skip to main content

Table 3 CMR findings

From: T1 and T2 mapping for evaluation of myocardial involvement in patients with ANCA-associated vasculitides

  Controls (n = 20) Patients (n = 37) p
LV-EF (%) 65 ± 4 64 ± 10 0.84
LV-EDV (ml) 109 ± 27 122 ± 41 0.38
LV-ESV (ml) 38 ± 13 46 ± 31 0.49
LV-SV 71 ± 15 76 ± 18 0.40
LV-EDD 45 ± 5 48 ± 5 0.08
LA (cm2) 20 ± 3 20 ± 5 0.84
IVS (mm) 10 ± 2 10 ± 2 0.11
PA (mm) 24 ± 4 25 ± 3 0.37
LV mass (g) 85 ± 20 90 ± 25 0.67
LGE - 16 (43%)  
epicardial - 5 (13%)  
intramural - 7 (19%)  
transmural - -  
subendocardial - 4 (11%)  
% LV mass - 6.8 ± 5  
Native T1 (ms) 952 (923–960) 988 (965–1017) <0.001
Post-contrast T1 (ms) 524 (500–529) 488 (468–528) 0.03
ECV (%) 24.5 (23–25) 27.5 (26–29) <0.001
T2 (ms) 49 (48–51) 53 (51–55) <0.001
  1. All values are n or mean ± SD or interquartile ranges. CMR cardiac magnetic resonance, LV left-ventricular, EF ejection fraction, EDV end-diastolic volume, ESV end-systolic volume, SV stroke volume, EDD end-diastolic diameter, LA left atrium, IVS interventricular septum, PA pulmonary artery, LGE late gadolinium enhancement, ECV extracellular volume